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The active center of human glutaredoxin (hGrx1) shares a common thioredoxin fold and specific affinity for substrate glutathione 
(GSH) with natural glutathione peroxidase (GPx). hGrx1 was redesigned to introduce the catalytic selenocysteine residue to imi-
tate the function of antioxidant selenoenzyme GPx in vivo. The human hGrx1 scaffold is a good candidate for potential medical 
application compared with other animal-originated protein scaffolds. Two consecutive rare codons (AGG-AGG) in the open 
reading frame of hGrx1 mRNA encoding Arg26-Arg27 residues can reduce seleno-hGrx1 expression level significantly in the Cys 
auxotrophic Escherichia coli strain BL21cysE51. Therefore, we optimized the rare codons, which resulted in a remarkable in-
crease of the expression level in the Cys auxotrophic cells, which may be sufficient for future medical production. The engineered 
artificial selenoenzyme displays high GPx catalytic activity, rivaling that of some natural GPx proteins. Kinetic analysis of the 
engineered seleno-hGrx1 showed a typical ping-pong kinetic mechanism; its catalytic properties are similar to those of some nat-
urally occurring GPx proteins. 
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Oxidative stress is associated with a wide range of human 
diseases, including atherosclerosis and related vascular dis-
eases, cancer, immunologic disorders, and neurodegenera-
tive diseases, either directly or indirectly. An increase in 
intracellular concentrations of oxidizing species, such as 
superoxide radicals, hydroxyl radicals, or hydrogen perox-
ide (H2O2), leads to the oxidation of proteins, DNA, and 
membranes, and thus mitochondrial dysfunction and ulti-
mately cell death [1]. Cells contain a large number of anti-
oxidants, including non-enzymatic and enzymatic antioxi-
dant systems to prevent or repair the damage caused by re-
active oxygen species, as well as to regulate redox-sensitive 
signaling pathways [2]. Antioxidant enzymes, including 
superoxide dismutase, which converts superoxide radicals 
to H2O2, and glutathione peroxidase (GPx) and catalase, 
which convert H2O2 to water, cooperate for protection 
against oxidative stress [3]. Intrinsic disadvantages of natu-
ral selenocysteine-containing GPxs have limited their ap-
plication, and many research efforts have been made to 
mimic the functions of GPx for potential medical applica-
tion. For example, the low-molecular-weight GPx mimic 
2-phenyl-1,2-benzoisoselenazol-3(2H)-one (Ebselen) has 
entered phase II clinical trials for the treatment of acute is-
chemic stroke [4]. However, there has been no report of a 
human natural protein scaffold that possesses a highly spe-
cific GSH-binding site for the design of a novel GPx mimic 
without immunogenicity for clinical application. 
The rational design of novel enzyme functions based on a 
detailed knowledge of protein structure, function, and cata-
lytic mechanism remains a major challenge and a funda-
mental goal for enzyme engineering, not only to generate 
new catalysts, but also to understand the catalytic mecha-
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nisms [5,6]. GPx is a well-known antioxidant selenoenzyme 
that catalyzes the reduction of lipid hydroperoxides to their 
corresponding alcohols and the conversion of free H2O2 to 
water with reduced glutathione, thus protecting cell com-
ponents from oxidative damage [7,8]. A great many at-
tempts have been made to redesign GPx because of poten-
tial medical importance as an antioxidant [9]. The rational 
design of a GPx mimic using natural protein scaffolds to 
introduce catalytic selenium at the active site has attracted 
considerable interest from biochemists in recent years. 
Based on the detailed structural and kinetic analysis of the 
natural GPx and its mutants, it was assumed that the high 
affinity of GSH toward the catalytic center and the optimum 
orientation of the sulfhydryl group of GSH to the catalytic 
selenium group would be critical for constructing a highly 
efficient GPx for catalyzing the reduction of H2O2 by GSH 
[10]. A GSH binding site has been successfully introduced 
into GPx models using a monoclonal antibody [11] and bio- 
imprinting techniques [12]. The resulting selenium-    
containing proteins exhibited high GPx activity. In addition, 
some intrinsic GSH-binding sites within the natural protein 
scaffolds have also been used to incorporate the catalytic 
selenium group for redesigned GPx mimics [13–16]. Fur-
thermore, glutathione S-transferase (GST), sharing a similar 
structure and GSH binding site with natural GPx, was rede-
signed to incorporate functional selenium and tellurium in 
an auxotrophic expression system. The redesigned artificial 
enzymes demonstrated a remarkable level of GPx activity 
[17,18]. For this proof-of-principle study, we wondered 
whether other GSH-binding proteins could be redesigned as 
a scaffold to incorporate the active selenium at the active 
center to mimic natural GPx. 
Glutaredoxin (Grx, EC 1.8.4.3), a well known enzyme 
with antioxidant function in vivo has an excellent affinity 
for the catalytic substrate GSH. Therefore, it could be used 
as a potential candidate for a protein scaffold to mimic GPx 
function. Furthermore, the yeast glutaredoxin has been re-
ported to have GPx activity, which increased its resistance 
to oxidative stress [19]. Bovine GPx was also found to have 
Grx activity, with nearly identical specificity constant for 
GSH to natural Grx [20]. Casi et al. [21] prepared sele-
no-glutaredoxin from Escherichia coli using chemical syn-
thesis in vitro; however, the GPx activity of the sele-
no-glutaredoxin was four orders of magnitude lower than 
that of bovine GPx. We previously engineered a seleno-Grx 
domain from mice, whose activity could rival several natu-
ral GPxs [22]. However, the engineered seleno-Grx from 
mice may induce immune reactions when used as antioxi-
dant for clinical application. Therefore, there is an urgent 
need to engineer a novel GPx model based on a human pro-
tein scaffold. 
Human glutaredoxin (hGrx1) shares a common thiore-
doxin fold and specific affinity for GSH with natural GPx, 
which makes it a good candidate as a scaffold for potential 
medical application. As shown in Figure 1, the active center  
 
Figure 1  (Color online) Schematic representation of the active site of the 
genetic engineered seleno-hGrx1 and the specific recognition of GSH. The 
structure of the wild-type hGrx1 is derived from the Protein Data Bank 
(1b4q). (a) The wild-type hGrx1 catalyzes the reduction of HED by GSH. (b) 
The catalytic center of hGrx1 was redesigned to introduce the catalytic Sec 
residue at position 22 to mimic GPx activity: the reduction of H2O2 by GSH. 
of hGrx1 was redesigned to introduce the catalytic seleno-
cysteine residue Sec22 for imitating the function of seleno-
enzyme GPx in vivo. However, the presence of two consec-
utive AGG-AGG rare codons encoding Arg26-Arg27 sig-
nificantly decreased the expression of seleno-hGrx1 mRNA 
in the Cys auxotrophic E. coli strain BL21cysE51. We thus 
employed a novel strategy for optimizing rare codons 
(shown in Figure 2), resulting in a remarkable increase in 
the expression level in Cys auxotrophic cells, which is suf-
ficient for potential future medical production. 
1  Materials and methods 
1.1  Materials  
The hGrx1 gene in plasmid pGEX-T was a generous gift 
from Prof. Christian Salesse from Laval University, Quebec 
City, Canada. The mutant hGrx1 (C7S, C25S, C78S, C82S) 
was kindly donated by Dr. John J. Mieyal from Case West-
ern Reserve University, Cleveland, OH, USA. E. coli strains, 
including DH5α, BL21(DE3), BL21-CodonPlus-RIL, and 
the expression vector PET-22b, were purchased from No-
vagen. The special cysteine auxotrophic E. coli strain 
BL21cysE51, which was used for introducing the catalytic 
residue of selenocysteine, was donated by Dr. August Böck 
from Ludwig-Maximilian University, Munchen, Germany. 
M9 minimal medium was used as previously described, 
with minor modifications [23]. Selenocysteine in the M9 
production medium was utilized at a concentration of 200 
mg/L. The pX plasmid was prepared from the host E. coli 
strain BL21-CodonPlus-RIL. T4 DNA ligase, Taq poly-
merase, Pfu polymerase, and Dpn I were from MBI Fer-
mentas, Vilnius, Lithuania. The plasmid Mini-Prep Kit, 
DNA Gel Extraction Kit, and all the primers for polymerase 
chain reaction (PCR) were purchased from Sangon, Shang-
hai, China. The Glutathione Sepharose 4B affinity column 
and all the other protein purification columns were from GE 
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Figure 2  (Color online) Schematic representation of the expression of 
human seleno-hGrx1 containing consecutive rare codons in the cysteine 
auxotrophic E. coli strain BL21cysE51. (a) The natural cysteine auxo-
trophic expression host E. coli strain BL21cysE51 does not successfully 
express seleno-hGrx1 because of intrinsic consecutive rare codons. (b) The 
transformed plasmid pX encodes an Arg-tRNA that could match consecu-
tive rare codons in the mRNA of hGrx1 well. (c) The translation of sele-
no-hGrx1 in the expression host. 
Healthcare Life Sciences, Uppsala, Sweden β-hydroxyethyl 
disulfide (HED), glutathione reductase (GR), and sele-
no-L-cysteine were purchased from Sigma-Aldrich, St. 
Louis, MO, USA. NADPH was from Roche China Co. 
(Shanghai, China). 
1.2  Construction of expression vector hGrx1-pET-22b 
hGrx1 was cloned into the cloning vector pGEM-T Easy 
(Promega) and the recombinant plasmid was used as a tem-
plate for PCR to prepare the hGrx1 gene using the upper pri-
mer 5′-GGAATTCGCATATGGCTCAAGAGTTTG-3′ and 
the lower primer 5′-AGTGAAGCTTCTGCAGAGCTCCA- 
AT-3′ containing restriction enzymes cleavage sites for 
Hind III and Nde I, respectively. The pET-22b expression 
vector and the hGrx1 PCR product were digested with Hind 
III / Nde I, followed by purification with DNA Gel Extraction 
Kit (Sangon, Shanghai, China), and then ligated together us-
ing T4 DNA ligase at 16°C overnight [24]. The recombinant 
hGrx1-pET-22b was sequenced to check integrity. 
1.3  Overexpression and purification of wild-type 
hGrx1 
The recombinant hGrx1-pET22b was transformed into E. 
coli strain BL21-CodonPlus-RIL. The expressed hGrx1 was 
extracted from the bacterial cells, applied to a GSH affinity, 
and competitively eluted from the column by GSH. The 
eluate was concentrated and then applied to a 2.6 cm × 80 
cm column of Sephadex G-50 at a flow rate of 0.5 mL/min 
with 0.05 (mol/L) sodium phosphate buffer, pH 7.0 contain-
ing 0.15 (mol/L) NaCl. The salt content was removed using a 
desalting column Sephadex G-25 column (1.8 cm × 40 cm). 
The purity of the sample was verified by SDS-PAGE. 
1.4  Overexpression and purification of seleno-hGrx1 
The recombinant hGrx1-pET22b was transformed into cys-
teine auxotrophic E. coli strain BL21cysE51. Overexpres-
sion of seleno-hGrx1 in the presence of Sec instead of Cys 
was performed as described for (Se)2-thioredoxin, except 
that the target protein was induced at low temperature of 
20°C [23]. The protein was also purified by affinity chro-
matography on Glutathione Sepharose 4B. The protein 
eluted from the column was further concentrated with Ul-
trafree-15 centrifugal concentrators (MWCO 3,000, Milli-
pore, Billerica, MA, USA), loaded onto a Sephadex G-50 
column, and eluted with 0.05 (mol/L) sodium phosphate 
buffer, pH 7.0 containing 0.5 (mol/L) NaCl. The seleno- 
hGrx1 fraction was concentrated and loaded to Sephadex 
G-25 column to remove the salt contents and finally lyophi-
lized. The purity of the sample was verified by SDS-PAGE. 
1.5  Determination of the protein concentration 
Protein concentration was determined by Bradford protein 
assay (Bio-Rad, Hercules, CA, USA) using bovine serum 
albumin as the standard [25]. 
1.6  Determinations of enzyme activities 
Enzyme activities were measured according to Wilson’s 
method [26]. The reaction was carried out at 37°C in 500 L 
of reaction solution containing potassium phosphate buffer 
50 mmol/L, pH 7.0, 1.0 mmol/L GSH, 0.4 units of GR, and 
0.5–2.5 μg of enzyme. The mixture was preincubated for 5 
min, and 50 L of NADPH solution (2.5 mmol/L) was  
added. After incubation for another 3 min at 37°C, the reac-
tion was initiated by adding 50 L of the second substrate 
peroxide, such as at a final concentration of 0.5 mmol/L 
H2O2, 0.25 mmol/L cumene hydroperoxide (CumOOH), or 
0.25 mmol/L tert-butyl hydroperoxide (t-BuOOH). 
Grx activities of the wild-type and seleno-hGrx1 were 
determined according to Holgmren’s method [27,28]. The 
reaction was carried out at 25°C in 500 L of the reaction 
mixture containing potassium phosphate buffer 50 mmol/L, 
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pH 7.0, 0.2 mmol/L NADPH, 1 mmol/L GSH, 1 mmol/L 
EDTA, 0.4 units GR, 0.5 mol/L HED, 0.5–5 μg of enzyme. 
1.7  Determination of optimal pH and temperature for 
seleno-hGrx1 catalysis 
The initial rates were measured using 1 mmol/L GSH and 
0.5 mmol/L H2O2. The pH value of the buffer varied from 
6.0 to 10.0 to determine the optimal pH condition for the cat-
alyzed reaction. Similarly, a series of seleno-hGrx1catalyzed 
reactions were carried out at different temperatures from 25 
to 55°C to determine the optimal temperature for the reaction. 
1.8  Steady-state kinetics of seleno-hGrx1 catalyzed 
reaction 
The kinetics analysis of seleno-hGrx1 catalyzed reduction 
of H2O2 by GSH was similar to that of selenium-containing 
seleno-LuGST1-1 [17]. The initial rates were determined by 
observing the decrease in NADPH absorption at 340 nm  
at a wide range of concentrations of one substrate while  
the concentration of the other was kept constant. All kinetic 
experiments were performed in a total volume of 0.5 mL 
containing potassium phosphate buffer 50 mol/L, pH 7.0, 1 
mol/L EDTA, 0.4 unit of GR, 0.25 mol/L NADPH, and var-
ying concentrations of GSH or H2O2, and seleno-hGrx1. 
After the preincubation of enzyme with GSH, NADPH,  
and GR for a few minutes, the reaction was then initiated by 
the addition of H2O2. The decrease in absorption without 
enzyme was recorded and subtracted as background. 
2  Results 
2.1  Preparation and isolation of seleno-hGrx1 
The preparation method was based on the assumption that 
an efficient charging of tRNACys with selenocysteine instead 
of cysteine by cysteinyl-tRNA synthetase occurred when 
selenocysteine was substituted for cysteine in the culture 
medium. Thus a selenocysteine residue could replace the 
cysteine residue in the expressed target protein by the cys-
teine auxotrophic strain E. coli BL21cysE51 [18,23]. In the 
case of human glutaredoxin hGrx1, the active residue Cys22 
was preserved and then converted to Sec22 during the ex-
pression in the host cells BL21cysE51. However, the other 
four non-specific cysteine residues (Cys7, Cys25, Cys78 
and Cys82) would be all substituted by Sec nonspecifically 
and thus hamper the interpretation of the kinetic perfor-
mance for the seleno-hGrx1 if all the five Cys residues were 
preserved. Therefore, the other four Cys residues, except 
Cys22, were mutated to Ser residues before introducing 
selenocysteine at the position Cys22 of hGrx1. The 4 other 
cysteine residues are not close to the active site and they do 
not form disulfide bridges; therefore, the substitutions were 
expected to have no effect on protein folding or catalytic 
performance [29]. 
The expression level of seleno-hGrx1 expression in E. 
coli BL21cysE51 increased nearly 5-fold after the rare co-
dons were optimized, compared with that without codon 
optimization (Figure 3(a)). The production of the artificial 
selenoenzyme was about 15% of the total proteins ex-
pressed in the cell, as estimated by analysis on SDS-PAGE, 
both in an active soluble form and as an inactive in inclu-
sion bodies (Figure 3(b)). A high yield of soluble purified 
protein was achieved at 2 mg/L of E. coli culture for sele-
no-hGrx1. 
2.2  Peroxidase and Grx activities of seleno-hGrx1 
The GPx and Grx activities of seleno-hGrx1 and other cata-
lysts are listed in Table 1. When HED was used as the sub-
strate, the Grx activity of seleno-hGrx1 (165 U/μmol) was 
nearly four times lower than that of wild-type hGrx1 (818 
U/μmol) under the same conditions. This may be due to the 
removal of the active Cys22 thiol group, which would in-
volve nucleophilic attack on the glutathionyl disulfide bond 




Figure 3  SDS-PAGE of the seleno-hGrx1 during expression and purifi-
cation. (a) Lane 1, protein molecular weight markers; lanes 2 and 3 are the 
whole cell extract before and after IPTG induction, respectively, without 
rare codon optimization; lanes 4 and 5 are the same as lanes 2 and 3 but 
with rare codon optimization. (b) Lane 1, the whole cell extract without 
IPTG induction; lane 2, the whole cell extract with IPTG induction; lane 3, 
supernatant of fragmented cells; lane 4, precipitate of fragmentized cells; 
lane 5, purified seleno-hGrx1 from the glutathione affinity column. 




Wild-type hGrx1 H2O2 5.2 
 HED 818 
Seleno-hGrx1 H2O2 136 
 CumOOH 105 
 t-BuOOH 121 
 HED 165 
Ebselen [31] H2O2 0.99 
Selenosubtilisin H2O2 4.6 
Seleno-LuGST1-1 [17] H2O2 2957 
Human plasma pGPx [32] H2O2 302 
Rabbit liver GPx [33] H2O2 5780 
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The GPx activities of the wild-type hGrx1 and sele-
no-hGrx1 were estimated by a coupled enzyme system un-
der the same conditions. Wild-type hGrx1 showed little 
GPx activity, whereas seleno-hGrx1 displayed an excellent 
activity of 136 U/μmol (Table 1). The seleno-hGrx1 cata-
lyzed reaction rate was proportional to the concentration of 
enzyme (Figure 4). The GPx activity of seleno-hGrx1 in 
catalyzing the reduction of H2O2 by GSH could be attribut-
ed to the Sec22 residue. Although seleno-hGrx1 was less 
efficient than some natural GPx for the reduction of H2O2 
by GSH, it was at least 30-fold and 137-fold more efficient 
than the first semisynthetic GPx mimic selenosubtilisin and 
the well-known GPx model compound Ebselen [31]. Its 
activity was even comparable with those of human natural 
GPx, such as human plasma pGPx whose activity was 302 
U/μmol [32]. 
2.3  Optimal pH and temperature for seleno-hGrx1 
catalyzed reduction of H2O2 by GSH 
The GPx activity of seleno-hGrx1 was examined over a 
wide range of pH values (from 6.0 to 10.0) and tempera-
tures (from 25.0 to 55.0°C). Figure 5 shows that the optimal 
pH of seleno-hGrx1 was 7.6, slightly lower than that of nat-
ural GPx (8.8), and the optimal temperature of sele-
no-hGrx1 was 48°C, which was near the optimal value for  
 
 
Figure 4  Absorbance vs. time during the catalytic reduction of H2O2 by 
GSH monitored at 340 nm for NADPH decrease with different concentra-
tion of enzyme. (a) in the absence of the enzyme sample; (b) 0.07 μmol/L; 
(c) 0.2 μmol/L; (d) 0.4 μmol/L. 
 
Figure 5  Effects of pH and temperature on GSH-dependent GPx activity 
of seleno-hGrx1. (a) Relative GPx activity as a function of pH. (b) Relative 
GPx activity as a function of temperature. The activity was determined at 
the concentrations of 1mmol/L GSH and 0.5 mmol/L H2O2. The activity 
detected at 37°C and pH 7.0 was defined as 100%. 
natural GPx (55°C) [34]. The GPx activities of sele-
no-hGrx1 at 37°C and pH 7.0 were 56% and 64% of their 
maximums of 243 U/μmol at 48°C, pH 7.0 and 212 U/μmol 
at pH 7.6, 37°C, respectively. 
2.4  Steady-state kinetics and catalytic mechanism of 
seleno-hGrx1 
The initial rates for H2O2 reduction catalyzed by sele-
no-hGrx1 were determined as a function of substrate con-
centration at 37.0°C, pH 7.0 when the concentration of one 
substrate was varied while the other was fixed. The initial 
reaction followed Michaelis-Menten kinetics. Double re-
ciprocal plots of the initial rate against substrate concentra-
tion revealed the characteristic parallel lines of a ping-pong 
mechanism, analogous to natural GPx [34] (Figure 6). The 
enzyme lost GPx activity completely in the presence of 
GSH and excess iodoacetate, suggesting the presentation of 
the enzyme-bound selenol in the catalytic cycle [35]. The 
further characterization of the catalytic mechanism and in-
termediates need to be fully demonstrated. 
3  Discussion 
Oxidative stress is associated with a wide range of human 
diseases either directly or indirectly. An increase in the 
concentrations of oxidizing species would destroy cellular 
redox balance and lead to the oxidation of proteins, DNA, 
membrane lipids, and thus mitochondrial dysfunction and 
ultimately cell death [36]. Anti-oxidative enzymes, such as 
superoxide dismutase, catalase, and GPx, are the three ma-
jor reactive oxygen species scavengers in cells and hence 
protect cells against oxidative damage. The most efficient 
means of scavenging H2O2 is mediated by GPx. The intrin-
sic disadvantages of natural GPx such as difficulty of het-
erogeneous expression limit its biomedical application. 
Therefore, much effort has been made to mimic the function 
of GPx using protein scaffolds and small molecules as hosts 
to which the catalytic selenium is introduced for therapeutic 
applications. To date, however, there is no GPx model 
based on a human protein scaffold with an intrinsic GSH 
binding site for potential clinical application without im-
mune reactions. 
A great many diseases are associated with oxidative 
stress, forming the basis of antioxidant therapy for these 
diseases. Ebselen, a synthetic seleno-organic compound, 
exhibits GPx-like activity of 0.99 U/μmol. It has been 
proven to possess several pharmacodynamic properties, 
including GPx-like activity and antioxidant activity. It is in 
phase II clinical trials for the treatment of acute ischemic 
stroke. Compared with the GPx-like activity of Ebselen, the 
GPx activity of seleno-hGrx1 is 136 U/μmol, about 136 
times higher than that of Ebselen. Thus seleno-hGrx1 is 
should be sufficient as an antioxidant drug, especially as it  
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Figure 6  Double-reciprocal plots for the reduction of H2O2 by GSH catalyzed by seleno-hGrx1. (a) [E]/v0 vs. 1/[GSH] (mmol/L) at [H2O2] = 0.2 mmol/L 
(■), 0.5 mmol/L(●), and 1 mmol/L (▲). (b) [E]/v0 vs. 1/[H2O2] (mmol/L) at [GSH] = 0.5 mmol/L (■), 1 mmol/L (●), and 2 mmol/L (▲). 
should have no immunogenicity to humans. 
The rational redesign of a novel non-immunogenic en-
zyme for medical application is a challenge for biochemists 
and pharmaceutical chemists. To date, few examples of re-
designed artificial enzymes that could match the catalytic 
efficiency of natural enzymes have been observed [37]. In-
spired by the successful redesign of seleno-GST [17] and 
telluro-GST [18], Grx was selected as an excellent scaffold 
for introducing GPx function because of the overall struc-
tural similarity in the GSH-binding domain between Grx 
and GPx. The seleno-Grx from E. coli did not display high 
GPx activity when the functional selenium was chemically 
introduced at the GSH binding site of Grx to simulate GPx 
activity [21]. By contrast, engineering the Grx domain of 
mouse thioredoxin/glutaredoxin reductase by substituting 
Cys with Sec at the active site of Grx presented excellent 
catalytic performance. However, the immunogenicity and 
safety to humans of seleno-Grx from mouse limited its fur-
ther therapeutic application as an antioxidant. Therefore, it 
is of great importance to explore human protein scaffolds 
that mimic GPx function for clinical applications. 
Human Grx1 is a 12 kD thiol-disulfide oxidoreductase 
that appears to have a critical role in maintaining the redox 
environment of the cell and thus protects the organism from 
oxidative damage. Previous studies have demonstrated that 
yeast Grx, mouse Grx2, and human mitochondrial Grx2 
exhibited GPx activity [19,38]. Furthermore, synthetic sele-
nium-containing Grx3 analogs have been reported to be 
highly reducing oxidoreductases with enhanced catalytic 
efficiency [39]. Considering all these previous studies, and 
the overall structural similarity between GPx and Grx, the 
evolutionarily related enzyme hGrx1 should provide an ex-
cellent potential protein scaffold. 
To convert wild-type hGrx1 into a selenium-containing 
enzyme, the catalytic Sec residue was incorporated into the 
GSH-binding site of hGrx1 by substituting the active site 
Cys22 with Sec22 using Cys auxotrophic E. coli strain 
BL21cysE51. To avoid the conversion of the other four 
non-active Cys residues to Secs, they were mutated to Ser 
residues before expression in the Cys auxotrophic cells 
(Figure 1). The four Cys quadruple mutant of hGrx1 (C7S, 
C25S, C78S, and C82S) displayed the same catalytic effi-
ciency (Vmax/KM) and specificity for glutathionyl mixed di-
sulfide substrate as that of the wild-type hGrx1 [29]. The 
quadruple mutant was transformed into the Cys auxotrophic 
E. coli strain and expressed, leading to the specific conver-
sion of the active site Cys22 to the catalytic Sec22. 
The presence of two consecutive AGG-AGG rare codons 
for Arg26-Arg27 residues in the reading frame reduced the 
seleno-hGrx1 expression level significantly in the Cys aux-
otrophic E. coli strain BL21cysE51 [40]. Therefore, a novel 
strategy for optimizing the rare codons was devised for the 
Cys auxotrophic E. coli strain (Figure 2). The Cys auxo-
trophic E. coli strain was transformed with plasmid pX en-
coding an Arg-tRNA that could recognize the rare codons in 
the mRNA of hGrx1. This strategy resulted in a remarkable 
increase in the expression level of seleno-hGrx1 in the Cys 
auxotrophic cells (Figure 3). The expression of the sele-
no-hGrx1 was induced at a low temperature of 20°C to in-
crease its active soluble fraction and decrease the formation 
of inactive inclusion bodies. The specific affinity of sele-
no-hGrx1 for GSH was used to purify the target protein by 
GSH affinity chromatography. 
The engineered seleno-hGrx1 displayed GPx-like perox-
idase activity (Table 1). The GPx activity of the engineered 
seleno-hGrx1 could be mainly attributed to the presence of 
a more active selenol group compared with the activity of 
the thiol group. Organic selenium compounds are more re-
active as nucleophiles than their sulfur counterparts, as the 
pKa of the selenol group (5.7 in free Sec) is three pKa units 
lower than that of the thiol group (8.5 in free Cys). Both 
free Cys and Sec were expected to be 1 pKa unit higher 
within a polypeptide chain [41]. Seleno-hGrx1 showed a 
26-fold increase in GPx activity over the wild-type hGrx1. 
Modification of the active center of the Sec46Cys mutant of 
phospholipids GPx was 1000-fold less active than the 
wild-type enzyme [42]. Therefore, selenium in Sec residue 
acted as a strong nucleophile and leaving group in the cata-
lytic cycle, indicating that the enhanced GPx activity was 
mainly attributed to the substitution of the catalytic Cys22 
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by a more reactive Sec residue. 
The GPx activity of seleno-hGrx1 was about 22-fold 
lower than that of the engineered seleno-LuGST-1 we pre-
pared previously [17]. However, it was still close to some 
natural GPxs, such as human plasma pGPx. This indicated 
that the GPx catalytic activity depended on the catalytic Sec 
residue and on some other residues such as the catalytic 
triad in the active site. 
Previous studies have proposed that Grx and GPx share a 
common “GSH-binding protein” ancestor, based on the 
similarities in their overall structures and the arrangement of 
their catalytic residues, despite their low sequence identity 
and functional differences [43,44]. Engineering hGrx1 into 
an efficient GPx mimic by the conversion of the catalytic 
Cys22 at the GSH-binding site to Sec22 provides additional 
proof for the previous assumption that their active-site resi-
dues have evolved independently from their common thi-
oredoxin-like ancestor to accommodate different functions 
and perform various activities in organisms [45,46]. 
In conclusion, we successfully redesigned and prepared 
human seleno-hGrx1 by substituting the catalytic residue 
Cys22 with Sec22 using the Cys auxotrophic expression 
system, where the four other Cys residues were mutated to 
Ser residues. The expression level of seleno-hGrx1 in cys-
teine auxotrophic cells increased five-fold after rare codon 
optimization. Based on the distinct structural similarities in 
the specific GSH binding site and geometric orientation of 
the catalytic Sec residue between seleno-hGrx1 and natu-
rally occurring GPx, the engineered seleno-hGrx1 demon-
strated excellent catalytic efficiency. However, its GPx ac-
tivity was an order of magnitude lower than some of natu-
rally occurring GPx. The engineered seleno-hGrx1 provides 
a suitable enzymatic model for further understanding of the 
relationship between the structure and function of GPx. In 
addition, the novel redesigned seleno-hGrx1 from a human 
protein scaffold will be a potential candidate as an antioxi-
dant for medical applications because of its low molecular 
weight and lack of immunogenicity for humans. 
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